Catalog Number:82031

IntelliPlex™ Lung Cancer Panel - cfRNA

The IntelliPlex™ Lung Cancer Panel comprises NSCLC driver genes' DNA mutations and RNA fusion variants detection for use with samples extracted from NSCLC formalin-fixed paraffin-embedded tissues (FFPET) or liquid biopsies such as plasma.
The cfRNA panel is a qualitative molecular assay for the detection of 28 RNA variant hotspots in ALK, ROS1, RET, NTRK1, and MET genes from plasma samples in a single well by using PlexBio's core πCode technology.

FEATURES
  • Detect 5 driver genes, 28 RNA fusion variants in one well test
  • Highly sensitive (10~89 copies) to detect low levels of RNA variants
  • Only ≥50ng RNA sample required
  • Time to results in <6 hours for 96 samples per run (sample preparation included)
broad coverage

Broad Target Coverage

Detectable 5 driver genes,
28 RNA variants in one well
sample

Low Sample Input

Only ≥50ng RNA sample extracted from FFPE tissues required
high sensitivity

High Sensitivity

Detects low levels of RNA variants with a high sensitivity
quick turnaround time

Quick Turnaround Time

Sample to results in <6 hours with automated reporting 
Overview
Most cases of lung cancer are sporadic, rather than hereditary, but several genes and even types of specific mutations are commonly seen in these sporadic cases. Due to the genetic diversity in lung cancers, a comprehensive and rapid test that access multiple genes' mutation profile simultaneously with a high level of accuracy, rather than individual gene testing is crucial and unmet need. Moreover, results are intended to assist clinicians in identifying patients who may benefit from available targeted treatments to achieve the personalized cancer management.

The IntelliPlexTM Lung Cancer Panel- cfRNA is an in-vitro molecular test based on πCodeTM technology and PlexBio's instrument platform to identify 28 RNA fusion variants in ALK, ROS1, RET, NTRK1, and MET genes in NSCLC. πCode technology enables the multi-variants detection in single-well with RNA samples derived from plasma. The kit provides all necessary optimized reagents for the sensitive detection of low levels of RNA variants in a background of wild-type genomic RNA by one-step RT-PCR and simultaneous PCR amplification of target cDNA. The genetic status evaluation from these NSCLC driver genes can impact the selection of and the response to targeted therapies.


Principle of πCode Multiplexing
OUR RESOURCES
IFU
Type
IFU
Publish Date
2022.05.06

您目前為透過後台登入模式

Please Enable cookies to improve your user experience

Continue